RxDoctor Payments Data

Dalailah de la Rosa

Nurse Practitioner · Corpus Christi, TXNPI 1962947242

Payments from drug & device makers

$2,633in general payments, 2019–2025

Across 152 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$641
  • GSK$392
  • Amgen$330
  • Novo Nordisk$320
  • Exact Sciences$174
  • Lundbeck LLC$160
  • plus $616 from 11 others

What the payments were for

  • Food & beverage$2,52296%
  • Education$1124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,633 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$29,347
Medicare patients
83
Services billed
493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide158$203,905
OzempicSemaglutide138$146,044
Repatha PushtronexEvolocumab49$40,954
EliquisApixaban34$37,721
XifaxanRifaximin13$36,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,576
Repatha SureclickEvolocumab40$26,878
ProliaDenosumab13$22,764
JardianceEmpagliflozin23$21,702
MyrbetriqMirabegron16$20,910
SymbicortBudesonide/Formoterol Fumarate47$16,653
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$14,831
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$11,227
LinzessLinaclotide12$9,109
Repatha SyringeEvolocumab17$8,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$641$203,905158 claims
Novo NordiskOzempic$320$146,044138 claims
PfizerEliquis$53$37,72134 claims
GSKTrelegy Ellipta$392$30,57639 claims
AmgenProlia$330$22,76413 claims
Boehringer IngelheimJardiance$21$21,70223 claims
Astellas Pharma US IncMyrbetriq$102$20,91016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →